Delayed US approval will hit Leo Pharma at full strength this year

Having first rejected eczema treatment tralokinumab, it took the US Food and Drug Administration eight additional months to approve the drug, a delay that had great consequences for developer Leo Pharma. Acting CEO Anders Kronborg says the FDA’s blow will begin to be felt for real this year.

Anders Kronborg, CFO and acting CEO at Leo Pharma until April | Photo: Martin Lehmann

Leo Pharma’s annual report published Thursday shows the repercussions from May of last year, when the US Food and Drug Administration decided not to grant the otherwise expected approval to atopic eczema drug tralokinumab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs